Drug Profile

Suramin sodium - Kuzani Pharmaceuticals

Alternative Names: KZ-101

Latest Information Update: 31 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kuzani Pharmaceuticals
Class Antiprotozoals; Behavioural disorder therapies; Naphthalenesulfonates
Mechanism of Action DNA synthesis inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Pervasive child development disorders

Most Recent Events

10 Mar 2025 Preclinical trials in Pervasive child development disorders in USA (IV)
10 Mar 2025 Children's Hospital of Orange County in collaboration with Kuzani Pharmaceuticals plans the phase II STAT-2A trial for Pervasive child development disorders (In Children) (IV, Infusion) (NCT06866275)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com